Pancreatic Cancer Research

ResearcherUniversity of Eastern FinlandNo recent work listed

Joel Isohookana

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5717-6662; OpenAlex author ID A5065733594. Sources: OpenAlex.

Their work

Papers
6
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 1 paper

Papers 6

  1. Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001195↗
  2. Proteins of the retinoblastoma pathway, FEN1 and MGMT are novel potential prognostic biomarkers in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.prp.2018.04.016↗
  3. Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-018-1432-4↗
  4. KDM4D Predicts Recurrence in Exocrine Pancreatic Cells of Resection Margins from Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.21873/anticanres.12474↗
  5. High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients. Co-author DOI 10.1007/s00428-017-2087-1↗
  6. Loss of Peroxiredoxin Expression Is Associated with an Aggressive Phenotype in Pancreatic Adenocarcinoma. Co-author PMID 26722077↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kirsi‐Maria Haapasaari · 6 shared papers, 2016–2019 · strength 0.55
  2. Peeter Karihtala · 4 shared papers, 2016–2019 · strength 0.40
  3. Joni Leppänen · 4 shared papers, 2017–2019 · strength 0.34
  4. Ylermi Soini · 3 shared papers, 2016–2018 · strength 0.31
  5. Joonas H. Kauppila · 3 shared papers, 2017–2019 · strength 0.24
  6. Heikki I. Huhta · 3 shared papers, 2017–2019 · strength 0.24
  7. Tuomo J. Karttunen · 3 shared papers, 2017–2019 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.